Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · RxSight, Inc. (RXST)

RxSight names Aziz Mottiwala CEO, replacing Ron Kurtz effective July 20, 2026

Neutral Impact 4 of 5 leadership Written later

RxSight's board appointed Aziz Mottiwala as President and Chief Executive Officer on July 13, 2026, effective July 20, 2026, replacing Ron Kurtz, M.D., who has led the company since 2016. Kurtz moves to Chief Medical Officer and resigns from the board, and Mottiwala joins the board in his place. The company said it is not updating its previously communicated financial guidance.

Key points

  • Mottiwala, 48, was Chief Commercial Officer of Tarsus Pharmaceuticals from August 2020 to July 2026.
  • Mottiwala's pay includes a $750,000 base salary, a 2026 cash bonus of $337,500, and equity awards with a grant-date value of $14,000,000.
  • Kurtz keeps a $740,000 base salary and can earn retention bonuses of $370,000 on each of four dates from January 1, 2027 through July 1, 2028, if he remains employed.
  • The company is not updating its previously communicated financial guidance in connection with the announcement.

The filing

CompanyRxSight, Inc. (RXST)
Form8-K, current report
Filed with the SECJul 15, 2026, 4:23 PM ET
Accession number0001193125-26-304812

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.